What to Expect From Abbott Laboratories' Next Quarterly Earnings Report

Core Insights - Abbott Laboratories (ABT) is a leading player in the in-vitro diagnostic market, with a market capitalization of $232.4 billion [1] - The company is expected to announce its fiscal Q3 earnings for 2025 on October 15, 2025 [1] Financial Performance Expectations - Analysts predict ABT will report a profit of $1.30 per share, reflecting a 7.4% increase from $1.21 per share in the same quarter last year [2] - For the full fiscal year, EPS is expected to be $5.15, a 10.3% increase from $4.67 in fiscal 2024, and projected to rise to $5.68 in fiscal 2026 [3] Stock Performance - ABT stock has increased by 18.5% over the past 52 weeks, outperforming the S&P 500 Index's 15.6% gain and the Health Care Select Sector SPDR Fund's 11.5% decline [4] - Following the Q2 results release, ABT's shares dropped 8.5% despite reporting a 7.4% year-over-year revenue growth to $11.1 billion and an adjusted EPS of $1.26, which was a 10.5% increase from the previous year [5] Analyst Ratings - The consensus opinion on ABT stock is bullish, with a "Strong Buy" rating from 19 out of 27 analysts, while the average price target is $144.48, indicating an 8.2% potential upside [6]